News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Toxicology Sinks Vernalis PLC, Biogen Idec, Inc. (Massachusetts)'s Parkinson’s Drug
July 16, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, July 16 (Reuters) - Vernalis (VER.L) has stopped development of a drug for Parkinson's disease that represented one of its main pipeline hopes, due to worries over adverse side effects, sending its shares 12 percent lower on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Phase 3
Preclinical
Europe
Biogen
MORE ON THIS TOPIC
Postmarket research
Amgen’s rare disease drug Tavneos tied to 20 deaths in Japan
May 18, 2026
·
2 min read
·
Tristan Manalac
Cancer
Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3
May 18, 2026
·
2 min read
·
Tristan Manalac
Drug Development
Genmab drops 2 antibody assets, including another ProfoundBio ADC
May 15, 2026
·
2 min read
·
Gabrielle Masson
Drug Development
Biogen’s Alzheimer’s results bolster tau theory—and Denali’s next gen candidate
May 15, 2026
·
3 min read
·
Annalee Armstrong